ABSTRACT
Objective To observe the efficacy of Danqi Yishen capsule in the treatment of diabetic nephrop-athy(DN),and the effect on laboratory indicators.Methods From March 2016 to December 2016,70 patients with DN in the Traditional Chinese Medicine Hospital of Shanxi Province were selected and divided into control group and observation group according to the different treatment method,with 35 cases in each group.The control group was given basic symptomatic treatment,and the observation group was given Danqi Yishen capsule on the basis of treat-ment in the control group.Both two groups were treated for 8 weeks.The clinical efficacy and changes of laboratory indicators were compared between the two groups.Results The total effective rate of the observation group was significantly higher than that of the control group (88.57% vs.62.86%),and the difference was statistically signifi-cant(P＜0.05).After treatment,the levels of fasting plasma glucose(FPG),2h postprandial blood glucose(2hPG),total cholesterol(TC),triglyceride(TG) and low-density lipoprotein cholesterol(LDL-C) in the observation group were (5.81 ±0.75)mmol/L,(7.64 ±2.12) mmol/L,(4.91 ±1.03) mmol/L,(1.71 ±0.46) mmol/L,(2.25 ± 0.69)mmol/L,respectively,which were significantly lower than those in the control group [(6.37 ±0.92)mmol/L,(8.96 ±1.97)mmol/L,(4.91 ±1.03)mmol/L,(2.17 ±0.52)mmol/L,(3.26 ±1.05)mmol/L](t ＝2.791,2.698,3.321,3.920,4.756,all P＜0.05).The levels of 24h urinary protein excretion(UAER),urinary β2-micro-globulin(β2-MG),urinary albumin and creatinine ratio(ACR) in the observation group were (104.12 ±0.61)mg/24h,(256.72 ±96.43)μg/L,(73.86 ±33.12),respectively,which were significantly lower than those in the control group [(139.87 ±38.45 ) mg/24h,( 431.12 ±97.84 ) μg/L,( 125.84 ±38.96 )] ( all P ＜0.05 ). Conclusion Danqi Yishen capsule can significantly relieve the clinical symptoms in patients with DN,and improve the therapeutic effect.Its mechanism may be associated with lowering blood glucose,regulating blood lipids and reducing urinary protein.